Kristen N Ganjoo
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr MC 5826 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Personal Information Email Tel (650) 498-6000Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Lymphoma
- Sarcoma
- Oncology
- Soft Tissue Sarcoma
- Gastrointestinal Stromal Tumors
- Ewing's Sarcoma
Administrative Appointments
- Assistant Professor of Medicine, Stanford University (2004 - present)
- Assistant Professor of Medicine, Indiana University (2000 - 2004)
Professional Education
| Residency: | Indiana University IN (1997) |
| Board Certification: | Oncology, American Board of Internal Medicine (2000) |
| Fellowship: | Indiana University School Of Medicine IN (2000) |
| Internship: | Indiana University IN (1995) |
| Medical Education: | University of South Alabama Medical Center AL (1994) |
| BS: | UC Davis, Biological Sciences (1989) |
Scientific Focus
Current Research Interests
Clinical research with new and novel therapies for lymphomas and sarcomas including anti-angiogenesis agents and hypoxia activating agents.
Clinical Trials
- Not Recruiting Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Not Recruiting Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
- Not Recruiting Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
- Not Recruiting Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
- Recruiting Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Publications
- The Treatment Outcome for Adult Patients with Ewing's Sarcoma. Curr Oncol Rep. 2013
- Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leuk Lymphoma. 2012; (4): 718-20
- Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest. 2012; (3): 231-5
- Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012; (5): 1395-403
- Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; (8): 951-60
- A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology. 2011; (1-2): 50-6
Help
Trial Administration